INCY Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 15.03% compared to Incyte's net margin of 19.72%. Incyte's return on equity of 0.57% beat Gilead Sciences's return on equity of 32.29%.

Incyte has a consensus price target of $75.41, signalling upside risk potential of 8.92%. On the other hand Gilead Sciences has an analysts' consensus of $116.85 which suggests that it could grow by 6.37%. Given that Incyte has higher upside potential than Gilead Sciences, analysts believe Incyte is more attractive than Gilead Sciences.

Incyte has a beta of 0.679, which suggesting that the stock is 32.054% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.84% to investors and pays a quarterly dividend of $0.79 per share. Incyte pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Incyte quarterly revenues are $1.1B, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Incyte's net income of $158.2M is lower than Gilead Sciences's net income of $1.3B. Notably, Incyte's price-to-earnings ratio is 216.34x while Gilead Sciences's PE ratio is 23.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.21x versus 4.82x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 15.03% compared to Incyte's net margin of 21.68%. Incyte's return on equity of 0.57% beat Eli Lilly and's return on equity of 78.25%.

Incyte has a consensus price target of $75.41, signalling upside risk potential of 8.92%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.57%. Given that Eli Lilly and has higher upside potential than Incyte, analysts believe Eli Lilly and is more attractive than Incyte.

Incyte has a beta of 0.679, which suggesting that the stock is 32.054% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Incyte pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Incyte quarterly revenues are $1.1B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Incyte's net income of $158.2M is lower than Eli Lilly and's net income of $2.8B. Notably, Incyte's price-to-earnings ratio is 216.34x while Eli Lilly and's PE ratio is 64.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.21x versus 14.56x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 15.03% compared to Incyte's net margin of 26.7%. Incyte's return on equity of 0.57% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Incyte has a consensus price target of $75.41, signalling upside risk potential of 8.92%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 32.96%. Given that Regeneron Pharmaceuticals has higher upside potential than Incyte, analysts believe Regeneron Pharmaceuticals is more attractive than Incyte.

Incyte has a beta of 0.679, which suggesting that the stock is 32.054% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.32% to investors and pays a quarterly dividend of $0.88 per share. Incyte pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Incyte quarterly revenues are $1.1B, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Incyte's net income of $158.2M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Incyte's price-to-earnings ratio is 216.34x while Regeneron Pharmaceuticals's PE ratio is 13.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.21x versus 4.44x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

UnitedHealth Group has a net margin of 15.03% compared to Incyte's net margin of 5.74%. Incyte's return on equity of 0.57% beat UnitedHealth Group's return on equity of 21.74%.

Incyte has a consensus price target of $75.41, signalling upside risk potential of 8.92%. On the other hand UnitedHealth Group has an analysts' consensus of $380.75 which suggests that it could grow by 30.18%. Given that UnitedHealth Group has higher upside potential than Incyte, analysts believe UnitedHealth Group is more attractive than Incyte.

Incyte has a beta of 0.679, which suggesting that the stock is 32.054% less volatile than S&P 500. In comparison UnitedHealth Group has a beta of 0.449, suggesting its less volatile than the S&P 500 by 55.115%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group offers a yield of 2.91% to investors and pays a quarterly dividend of $2.21 per share. Incyte pays -- of its earnings as a dividend. UnitedHealth Group pays out 52.29% of its earnings as a dividend. UnitedHealth Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Incyte quarterly revenues are $1.1B, which are smaller than UnitedHealth Group quarterly revenues of $109.6B. Incyte's net income of $158.2M is lower than UnitedHealth Group's net income of $6.3B. Notably, Incyte's price-to-earnings ratio is 216.34x while UnitedHealth Group's PE ratio is 12.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.21x versus 0.66x for UnitedHealth Group. Usually stocks with elevated PS ratios are considered overvalued.